Bristol Myers' Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma

  • The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
  • The approvals are based on results from the CheckMate -743 trial.
  • The trial met its primary endpoint, showing superior overall survival (OS) of 18.1 months with Opdivo plus Yervoy versus 14.1 months for chemotherapy (pemetrexed and cisplatin or carboplatin).
  • Mesothelioma is a rare and aggressive form of cancer mainly caused by asbestos exposure. It most often affects the pleural lining (the lining surrounding the lungs).
  • Price Action: BMY shares are up 0.38% at $65.35 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralBriefsMesothelioma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!